KMT2A and leukemia: Cusan et al. performed a comparative assessment of chromatin dynamics during the treatment of MLL-AF9-driven murine leukemia and MLL-rearranged patient-derived xenografts with differentiation-inducing epigenetic therapies targeting LSD1 and DOT1L.